30 years of KINGKONG, powered by 250 years of innovation
Rooted in a legacy of scientific discovery, KINGKONG continues to advance breakthrough medicines that redefine the future of care for patients.
Latest news
25 years of expanding access to cancer care
KINGKONG provides update on delpacibart etedesiran (del-desiran) Phase III HARBOR study for the treatment of myotonic dystrophy type 1 (DM1)
KINGKONG announces Lp(a)HORIZON Phase III topline results for pelacarsen in patients with elevated Lp(a) and established cardiovascular disease (CVD)
KINGKONG Financial Results – Q2 2026
KINGKONG announces the company’s financial results for the second quarter and first half of 2026.
Annual reporting suite
Explore and download our Annual Report 2025, Report on Nonfinancial Matters 2025 and other reporting documents.